Search - tctmd.com

Displaying 1 - 20 of 112

Sort: Relevancy | Date

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

News Daily News

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

L.A. McKeown

July 24, 2025

News Daily News

Prepregnancy CV Health Portends Midlife Risks: CARDIA Analysis

L.A. McKeown

June 27, 2025

News Daily News

Poor Cardiometabolic Health in Pregnancy Tied to Higher BP for Young Offspring

Caitlin E. Cox

May 15, 2025

News Opinion CV Team Dispatch

April 2025 Dispatch for the CV Team

L.A. McKeown

April 18, 2025

News Opinion CV Team Dispatch

March 2025 Dispatch for the CV Team

L.A. McKeown

March 21, 2025

News Opinion CV Team Dispatch

January 2025 Dispatch for the CV Team

L.A. McKeown

January 24, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

News Opinion CV Team Dispatch

November 2024 Dispatch for the CV Team

L.A. McKeown

November 26, 2024

News Features

Can ‘Body Roundness Index’ Replace BMI? That Depends, Say Experts

Michael O'Riordan

October 21, 2024

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

News Daily News

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

Michael O'Riordan

August 19, 2024

News Daily News

Semaglutide Has Similar Benefits in Women and Men With HFpEF

Todd Neale

June 26, 2024

News Daily News

AHA Celebrates a Century by Looking Back, and Forward

Shelley Wood

June 10, 2024

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

News Conference News

Lifestyle Changes Can Curb CVD Risk After Adverse Pregnancy Outcomes

Yael L. Maxwell

March 26, 2024

News Daily News

Universal Risk Tool Works Well in Both Primary and Secondary Prevention

Michael O'Riordan

February 01, 2024

News Opinion CV Team Dispatch

January 2024 Dispatch for the CV Team

L.A. McKeown

January 01, 2024

News Daily News

Mortality Risk Varies Among Patients With Very High LDL Levels

Michael O'Riordan

November 17, 2023

Advertisement

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

Prepregnancy CV Health Portends Midlife Risks: CARDIA Analysis

Poor Cardiometabolic Health in Pregnancy Tied to Higher BP for Young Offspring

April 2025 Dispatch for the CV Team

March 2025 Dispatch for the CV Team

January 2025 Dispatch for the CV Team

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

November 2024 Dispatch for the CV Team

Can ‘Body Roundness Index’ Replace BMI? That Depends, Say Experts

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

Semaglutide Has Similar Benefits in Women and Men With HFpEF

AHA Celebrates a Century by Looking Back, and Forward

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Lifestyle Changes Can Curb CVD Risk After Adverse Pregnancy Outcomes

Universal Risk Tool Works Well in Both Primary and Secondary Prevention

January 2024 Dispatch for the CV Team

Mortality Risk Varies Among Patients With Very High LDL Levels

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content